Ultragenyx Announces Data From Confirmatory Cohort Of Phase 1/2 Study Of DTX401 Gene Therapy For Glycogen Storage Disease Type Ia; Says 'All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use'
Benzinga Newsdesk